BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX: DDD - News) today announced the initiation of the first of three pivotal trials to evaluate the safety and efficacy of its over-the-counter (OTC) 12-hour CDT®-based ibuprofen. The Company expects to complete the trials by the end of the first quarter of 2008, and plans to file a New Drug Application with the Food and Drug Administration in the second half of 2008.
